Cytogen ratchets down

Cytogen ratchets down Cytogen Inc. announced a major cutback in research and staff, in response to both slow sales of its OncoScint imaging agent and the current health care environment.

Almost everything not in Phase III or beyond is being put in mothballs, President Thomas McKearn told BioCentury. That includes four imaging agents (OncoScint Colorectal CEA, OncoScint NSC Lung, OncoScint Breast and OncoScint Bladder) and three therapeutics (OncoRad Ovarian, OncoRad Prostate and OncoRad Bladder)...